Skip to main content
OSCR
NYSE Finance

Oscar Health Reports Significant Q1 Profitability Turnaround, Reaffirms 2026 Guidance

Analysis by Arik Shkolnikov
Sentiment info
Positive
Importance info
8
Price
$19.86
Mkt Cap
$4.764B
52W Low
$10.69
52W High
$23.8
Market data snapshot near publication time

summarizeSummary

Oscar Health reported a significant return to profitability in Q1 2026 with $679.0 million in net income and improved operational metrics, reaffirming its full-year guidance despite a revenue miss.


check_boxKey Events

  • Significant Profitability Turnaround

    The company reported a net income of $679.0 million for Q1 2026, a substantial increase from $275.3 million in Q1 2025 and a major reversal from the $443.15 million net loss in fiscal year 2025. Diluted EPS rose to $2.07 from $0.92 year-over-year.

  • Improved Operational Efficiency

    The Medical Loss Ratio (MLR) improved to 70.5% in Q1 2026 from 75.4% in Q1 2025, and the SG&A expense ratio decreased to 15.2% from 15.8%, reflecting disciplined pricing and cost management.

  • Reaffirmed Full-Year Guidance

    Oscar Health reaffirmed its full-year 2026 outlook across all metrics, signaling management's confidence in achieving meaningful profitability for the year, despite the Q1 revenue miss.

  • Strong Revenue Growth and Membership Increase

    Total revenue grew to $4.65 billion in Q1 2026 from $3.05 billion in Q1 2025, driven by a significant increase in total members to 3.17 million from 2.04 million year-over-year.


auto_awesomeAnalysis

Oscar Health announced a substantial improvement in its financial performance for the first quarter of 2026, reporting a net income of $679.0 million, a significant reversal from the prior year's net loss. This strong profitability, coupled with an improved Medical Loss Ratio (MLR) and SG&A expense ratio, indicates enhanced operational efficiency. Despite Q1 revenue falling short of analyst estimates, the company's decision to reaffirm its full-year 2026 guidance suggests confidence in its ongoing strategy and future performance. This turnaround is a critical development for investors, especially following the substantial net loss reported in the fiscal year 2025.

At the time of this filing, OSCR was trading at $19.86 on NYSE in the Finance sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $10.69 to $23.80. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed OSCR - Latest Insights

OSCR
May 07, 2026, 4:24 PM EDT
Filing Type: 10-Q
Importance Score:
9
OSCR
May 06, 2026, 6:19 AM EDT
Filing Type: 8-K
Importance Score:
8
OSCR
May 06, 2026, 6:00 AM EDT
Source: Reuters
Importance Score:
8
OSCR
Apr 22, 2026, 4:16 PM EDT
Filing Type: DEF 14A
Importance Score:
8
OSCR
Apr 07, 2026, 4:16 PM EDT
Filing Type: 4
Importance Score:
10
OSCR
Feb 13, 2026, 4:27 PM EST
Filing Type: 10-K
Importance Score:
9
OSCR
Feb 10, 2026, 6:25 AM EST
Filing Type: 8-K
Importance Score:
9